Overview

An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to assess the tolerability of AVANZ.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
ALK-Abelló A/S
Criteria
Inclusion Criteria:

- History of grass pollen rhinoconjunctivitis

- Positive SPT to Phleum pratense

- Positive specific IgE against Phleum pratense

Exclusion Criteria:

- Uncontrolled severe asthma